Abstract 950O
Background
Our previous meta-analysis showed that concomitant chemotherapy (CT) improved overall survival (OS) in patients with non-metastatic head and neck squamous cell carcinoma (HNSCC). The study purpose was to update patient follow up, gather data on toxicity and include randomized trials conducted up to 2010.
Methods
This individual patient data meta-analysis included trials comparing loco-regional treatment (LRT) to LRT + CT or induction CT + radiotherapy (RT) to RT + concomitant (or alternating) CT in non-metastatic HNSCC patients and conducted between 1965 and 2010. A fixed effect model was used. The log-rank test, stratified by trial, was used to compare treatments. OS was the primary endpoint.
Results
15 new trials (2,574 patients) were included. Updated data were obtained for 11 additional trials. For the comparison of LRT vs. LRT + CT, 94 trials (18,394 patients) with median follow-up of 6.7 years were analyzed. The most frequent tumor site was oropharynx (35%). Stage III and IV tumors represented 29% and 63% of patients. The addition of CT improved OS with a hazard ratio (HR) [95% confidence interval] of 0.89 [0.86; 0.92], p
Conclusions
This update of the MACH-NC meta-analysis confirms the superiority of concomitant CT for locally advanced HNSCC with longer follow-up, when compared to induction treatment. Study of patterns of relapse and toxicity is ongoing.
Clinical trial identification
Not applicable.
Legal entity responsible for the study
N/A
Funding
French Ministry of Health (Programme d'actions integrees de recherche VADS) Ligue Nationale Contre le Cancer French National Cancer Institute (SHS 2014-141) National Cancer Institute, National Institutes of Health (CA180888 and CA180819) Hellenic Cooperative Oncology Group (HE R_5G)
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort
Presenter: Neil Segal
Session: Head and neck cancers
Resources:
Abstract
Presentation
Webcast
Surrogate endpoints for overall survival in loco-regionally advanced nasopharyngeal carcinoma: Results from the individual patient data meta-analysis MAC-NPC2
Presenter: Federico Rotolo
Session: Head and neck cancers
Resources:
Abstract
Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC)
Presenter: Julie Bauman
Session: Head and neck cancers
Resources:
Abstract
PET-CT surveillance for advanced head and neck cancer: a cost-effective alternative to planned neck dissection?
Presenter: Alison Smith
Session: Head and neck cancers
Resources:
Abstract
Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055
Presenter: Robert Haddad
Session: Head and neck cancers
Resources:
Abstract
Invited discussant abstracts LBA36, 957PD and 955PD
Presenter: Ulrich Keilholz
Session: Head and neck cancers
Resources:
Presentation
Webcast
Invited discussant abstracts 952PD, 953PD and 956PD
Presenter: Ricard Mesia Nin
Session: Head and neck cancers
Resources:
Presentation
Webcast
Invited discussant abstracts 950O and 951O
Presenter: Ezra Cohen
Session: Head and neck cancers
Resources:
Presentation
Webcast
Invited discussant abstracts 949O and 954O
Presenter: Sandrine Faivre
Session: Head and neck cancers
Resources:
Presentation
Webcast
Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses
Presenter: Marcia Brose
Session: Head and neck cancers
Resources:
Abstract